Medical tourism regulation for embryo editing abroad

Introduction

Medical tourism regulation for embryo editing abroad refers to the legal and regulatory measures governing individuals who travel to foreign countries to obtain reproductive genetic procedures involving the modification of human embryos. These procedures may involve technologies such as CRISPR-Cas9 and other genome-editing techniques designed to alter genetic material before implantation.

Embryo editing has potential applications in genetic research and the study of inherited diseases. However, editing embryos intended for reproduction raises serious concerns because genetic changes may be passed to future generations. Potential risks include unintended genetic alterations, uncertain long-term effects, inadequate consent, and discrimination based on inherited characteristics.

Medical tourism creates additional legal difficulties because the patient's home country and the destination country may have different laws governing reproductive technologies. Clinics may attempt to attract international patients by offering procedures that are restricted or prohibited elsewhere. Therefore, effective regulation requires coordination between medical regulators, governments, research institutions, and international organisations.

Legal framework in India

1. Assisted Reproductive Technology (Regulation) Act, 2021

The ART Act, 2021, regulates assisted reproductive technology clinics and banks in India.

It establishes requirements concerning registration, professional qualifications, consent, record maintenance, and the operation of reproductive healthcare institutions.

Its relevance to embryo editing arises where the proposed procedure involves ART services or the handling of embryos within the statutory framework.

However, registration under the ART Act does not automatically authorise every form of embryo genome editing. A clinic must comply with all other applicable legal and regulatory restrictions.

2. Surrogacy (Regulation) Act, 2021

The Surrogacy (Regulation) Act, 2021, regulates surrogacy arrangements in India.

It establishes eligibility requirements and restrictions concerning surrogacy services and the operation of surrogacy clinics.

Medical tourism businesses cannot use foreign arrangements or artificial contractual structures to avoid applicable Indian legal requirements governing surrogacy.

3. Pre-Conception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994

The PCPNDT Act, 1994, prohibits sex selection and regulates prenatal diagnostic techniques.

Section 3A prohibits sex selection, while Section 6 prohibits the determination and communication of foetal sex, subject to the statutory framework.

This legislation is relevant where reproductive genetic services involve prohibited sex selection or are marketed as methods of selecting children according to sex.

4. National Guidelines for Stem Cell Research, 2017

The ICMR and Department of Biotechnology issued the National Guidelines for Stem Cell Research, 2017.

These guidelines establish ethical and scientific requirements for research involving human stem cells and related biological materials.

They distinguish between permitted research activities and prohibited or restricted applications. Research involving human embryos and reproductive genetic modification must be assessed under the relevant ethical and regulatory requirements.

5. Foreign Exchange Management Act, 1999

The Foreign Exchange Management Act, 1999, regulates specified foreign exchange transactions in India.

Payments made by Indian residents to overseas fertility clinics or biotechnology institutions must comply with applicable foreign exchange requirements.

However, compliance with foreign exchange regulations does not establish that the medical procedure itself is lawful.

6. Constitution of India

Article 21 protects life and personal liberty, including privacy, dignity, and reproductive autonomy.

Article 14 guarantees equality before the law.

These constitutional protections are relevant when evaluating reproductive decisions, genetic privacy, discriminatory practices, and access to medical services.

Major regulatory challenges in embryo-editing medical tourism

1. Differences between national laws

Countries have different approaches to embryo editing. Some permit certain forms of laboratory research, while others restrict or prohibit reproductive applications.

Patients travelling abroad may therefore encounter procedures that are not legally or scientifically established in their home countries.

2. Cross-border regulatory avoidance

Some clinics may advertise overseas procedures to attract patients seeking treatments unavailable in their home jurisdictions.

However, travelling abroad does not automatically remove legal obligations that may apply to patients, medical professionals, companies, or institutions under the relevant domestic laws.

3. Inadequate informed consent

Patients may not understand the difference between embryo screening and embryo genome editing.

They should receive clear information about:

The experimental nature of the proposed intervention.

Potential unintended genetic changes.

Uncertain long-term effects.

Available alternative reproductive options.

Regulatory approval and clinical evidence.

Financial costs and possible complications.

4. Patient protection and misleading advertisements

Overseas clinics may advertise embryo editing as a guaranteed method of preventing inherited diseases or producing genetically desirable children.

Such statements may exploit patients facing infertility or inherited medical conditions. Regulatory authorities should examine misleading claims and ensure that promotional material accurately represents scientific evidence.

5. Genetic privacy and data protection

International reproductive treatment may require transferring genetic reports, fertility records, family medical histories, and embryo-related information across national borders.

Such transfers raise questions concerning confidentiality, data security, consent, and the legal responsibilities of foreign healthcare providers.

6. Accountability for medical complications

When complications arise after treatment abroad, patients may face difficulties identifying the responsible clinic, obtaining medical records, initiating legal proceedings, or securing compensation.

Clear contractual documentation and accessible complaint procedures are therefore important.

International legal framework

1. Oviedo Convention, 1997

The Convention on Human Rights and Biomedicine addresses ethical and legal issues involving human genetics.

Article 13 restricts interventions seeking to modify the human genome except for preventive, diagnostic, or therapeutic purposes and subject to the condition that the intervention is not intended to introduce modifications in the genome of descendants.

It applies directly to countries that are parties to the Convention, not automatically to India.

2. UNESCO Universal Declaration on Bioethics and Human Rights, 2005

This declaration establishes principles concerning human dignity, informed consent, privacy, equality, and protection against exploitation.

It provides ethical guidance for international reproductive healthcare and genetic research.

3. WHO Recommendations on Human Genome Editing, 2021

The World Health Organization recommends international cooperation, transparent governance, regulatory oversight, and responsible management of human genome-editing technologies.

It also highlights the importance of addressing unregistered and unethical genome-editing activities.

4. International Covenant on Civil and Political Rights, 1966

Article 17 protects individuals against arbitrary or unlawful interference with privacy.

This protection is relevant to the handling of genetic information and reproductive medical records in international healthcare arrangements.

Important judicial decisions

There are no widely recognised Indian Supreme Court judgments directly addressing medical tourism specifically for reproductive embryo editing abroad. However, the following decisions establish relevant legal principles.

1. Suchita Srivastava v. Chandigarh Administration (2009)

The Supreme Court recognised reproductive autonomy as an important aspect of personal liberty under Article 21.

The judgment is relevant because overseas reproductive treatment must respect individual autonomy and should not involve coercion or manipulation of patients' reproductive decisions.

2. Justice K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right.

This decision is particularly relevant to international embryo-editing services because genetic information and reproductive medical records require strong privacy protection.

3. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court explained the legal requirements of informed consent in medical treatment.

Its principles are relevant when patients travel abroad for experimental reproductive procedures. Patients must understand the nature, risks, limitations, and alternatives of the proposed treatment.

4. Indian Medical Association v. V.P. Shantha (1995)

The Supreme Court held that medical services provided for consideration generally fall within consumer protection law, subject to recognised exceptions.

The decision provides important principles for addressing deficient medical services. Its application to overseas treatment, however, depends on jurisdiction and the facts of the dispute.

5. National Legal Services Authority v. Union of India (2014)

The Supreme Court recognised constitutional protections for gender identity and dignity.

Although the judgment did not concern embryo editing, its principles are relevant to preventing discrimination and protecting human dignity in reproductive and genetic healthcare.

Responsibilities of governments and healthcare institutions

Effective regulation requires cooperation between domestic and foreign authorities.

Important measures include:

Establishing clear restrictions on reproductive genome editing.

Monitoring advertisements promoting experimental procedures.

Requiring transparent disclosure of regulatory status.

Protecting genetic and reproductive information.

Strengthening international cooperation between medical regulators.

Establishing accessible patient complaint mechanisms.

Monitoring unethical cross-border reproductive arrangements.

Ensuring that healthcare professionals follow applicable scientific and ethical standards.

Governments should also distinguish legitimate reproductive genetic services, such as appropriately regulated genetic testing, from heritable genome-editing interventions.

Conclusion

Medical tourism regulation for embryo editing abroad is a complex area involving reproductive autonomy, international healthcare, genetic privacy, scientific safety, and cross-border legal accountability. Differences between national regulations can expose patients to unproven procedures and commercial exploitation.

In India, the ART Act, 2021, Surrogacy (Regulation) Act, 2021, PCPNDT Act, 1994, and constitutional protections provide important legal safeguards. International frameworks such as the Oviedo Convention and WHO recommendations provide additional guidance on responsible genome-editing governance.

Judgments such as Suchita Srivastava v. Chandigarh Administration, Justice K.S. Puttaswamy v. Union of India, and Samira Kohli v. Dr. Prabha Manchanda establish relevant principles concerning reproductive autonomy, privacy, and informed consent.

Ultimately, effective regulation requires international cooperation, transparent medical practices, strict oversight of experimental procedures, and protection against misleading commercial claims. These measures help ensure that reproductive genetic technologies are governed by scientific evidence, human dignity, and legal accountability.